Heterocyclic amides of formula (1) 1
wherein: 2
is a single or double bond;
A is phenylene or heteroarylene;
m is 0, 1 or 2;
n is 0, 1 or 2;
R.sup.1 is selected from for example halo, nitro, cyano, hydroxy, carboxy;
R.sup.2 is hydrogen, hydroxy or carboxy;
R.sup.3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl
and C.sub.1-4alkyl(optionally substituted by 1 or 2 R.sup.8 groups);
R.sup.4 is independently selected from for example hydrogen, halo, nitro,
cyano, hydroxy, C.sub.1-4alkyl, and C.sub.1-4alkanoyl;
R.sup.8 is selected from for example hydroxy, --COCOOR.sup.9,
--C(O)N(R.sup.9)(R.sup.10), --NHC(O)R.sup.9, (R.sup.9)(R.sup.10)N-- and
--COOR.sup.9;
R.sup.9 and R.sup.10 are selected from for example hydrogen, hydroxy,
C.sub.1-4alkyl (optionally substituted by 1 or 2 R.sup.13);
R.sup.13 is selected from hydroxy, halo, trihalomethyl and
C.sub.1-4alkoxy;
or a pharmaceutically acceptable salt or pro-drug thereof; possess
glycogen phosphorylase inhibitory activity and accordingly have value in
the treatment of disease states associated with increased glycogen
phosphorylase activity. Processes for the manufacture of said
heterocyclic amide derivatives and pharmaceutical compositions containing
them are described.
